ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The results revealed that exposure to RBC8 effectively prolonged the survival of CML mice driven by BCR-ABL1; furthermore, the combination of RBC8 with imatinib markedly prolonged the survival of CML mice.